Growth Opportunities in HPV Testing and Pap Test Market

The HPV test is used to diagnose the infection caused by HPV that mutates a normal cell into a cancerous cell and further leads to the development of genital warts, abnormal cervical cells, or cervical cancer. The growth of the HPV testing and Pap test market is mainly attributed to the increasing number of cervical cancer cases, growing the aging population, increasing awareness of cervical cancer screening programs, and government initiatives and funding

According to Latest Market research report Published by MarketsandMarkets the “HPV Testing and Pap Test Market Size, Share, Demand and Growth Analysis, forecast” the Global Market is expected to reach $ 4.52 billion, at a CAGR of 6.6%

key players operating in the Global HPV Testing and Pap Test Market;

Key players in the market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.)

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

Major Dynamics Impacting the HPV Testing and Pap Test Market;

· Growth Drivers:

1. An increasing number of cervical cancer cases and a growing aging population

2. Increasing awareness of cervical cancer screening programs

3. Government initiatives and funding.

· Restraints

1. Changes in regulatory guidelines for cervical cancer screening
2. HPV vaccination

Objectives of The Study-

• To define, describe, and segment the global HPV testing and Pap test market on the basis of test types, application, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze micro-markets with respect to individual growth trends, prospects, and contributions to the global HPV testing and Pap test market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players
• To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

Global HPV Testing and Pap Test Market Segmentation:

Based on the application, the Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is expected to grow at the highest CAGR during the forecast period, owing to the growing incidences of cervical cancer.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.

HPV Testing and Pap Test Market: Worldwide Industry Analysis and New Market Opportunities Explored

The report “HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End-User (Laboratories, Hospitals, Physicians’ Offices & Clinics) — Global Forecast”, published by MarketsandMarkets™

Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.

The HPV testing and Pap test Market is poised to reach USD 4,523.1 Million, at a CAGR of 6.6%

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

The increasing number of cervical cancer cases and the growing aging population

Cervical cancer is considered to be the fourth most prevalent forms of cancer globally and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012. This figure is expected to reach to 609,270 new cases and 315,727 deaths by 2020. (Source: Globocan 2012). Approximately 26,000 new cancers attributable to HPV occur each year, 18,000 among females and 8,000 among males (Source: CDC). The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. This, in turn is expected to drive the HPV testing and Pap test market in the coming years.

HPV Testing and Pap Test Market Drivers:

• The increasing number of cervical cancer cases and a growing aging population
• Increasing awareness of cervical cancer screening programs
• Government initiatives and funding.

Geographic Analysis:

• Detailed analysis of HPV testing and Pap test market in European countries such as the UK, Germany, France, Italy, Spain, and others

Geographically, the HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.

Request Research Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

Key players in the HPV testing and Pap test market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.). These players focus on inorganic and organic strategies such as product approvals & licenses, agreements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the HPV testing and Pap test market.